c-Kit (D816F)

KIT · Variant type: point · HGVS: p.D816F

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Nintedanib	99.7%	0.3%	90.23
2	Dasatinib	99.6%	0.4%	87.97
3	Avapritinib	99.3%	0.7%	97.73
4	Ripretinib	98.9%	1.1%	92.95
5	Selpercatinib	98.5%	1.5%	96.72
6	Brigatinib	98.5%	1.5%	82.96
7	Pralsetinib	97.7%	2.3%	93.43
8	Gilteritinib	97.3%	2.7%	88.97
9	Bosutinib	96.7%	3.3%	87.22
10	Erdafitinib	96.6%	3.4%	95.71
11	Ponatinib	95.6%	4.4%	78.23
12	Alectinib	93.8%	6.2%	95.49
13	Pazopanib	93.4%	6.6%	97.49
14	Mitapivat	92.0%	8.0%	100.00
15	Vandetanib	91.7%	8.3%	95.74
16	Sunitinib	91.2%	8.8%	91.73
17	Fostamatinib	89.3%	10.7%	96.74
18	Tivozanib	89.2%	10.8%	92.42
19	Pacritinib	89.1%	10.9%	88.64
20	Apatinib	84.8%	15.2%	97.73
21	Umbralisib	80.2%	19.8%	98.74
22	Fedratinib	79.0%	21.0%	96.21
23	Capivasertib	77.5%	22.5%	96.48
24	Binimetinib	72.5%	27.6%	100.00
25	Lorlatinib	71.3%	28.7%	97.24

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Nintedanib	99.7%	—	—
Dasatinib	99.6%	—	—
Avapritinib	99.3%	—	—
Ripretinib	98.9%	—	—
Selpercatinib	98.5%	—	—
Brigatinib	98.5%	—	—
Pralsetinib	97.7%	—	—
Gilteritinib	97.3%	—	—
Bosutinib	96.7%	—	—
Erdafitinib	96.6%	—	—
Ponatinib	95.6%	—	—
Alectinib	93.8%	—	—
Pazopanib	93.4%	—	—
Mitapivat	92.0%	—	—
Vandetanib	91.7%	—	—
Sunitinib	91.2%	—	—
Fostamatinib	89.3%	—	—
Tivozanib	89.2%	—	—
Pacritinib	89.1%	—	—
Apatinib	84.8%	—	—
Umbralisib	80.2%	—	—
Fedratinib	79.0%	—	—
Capivasertib	77.5%	—	—
Binimetinib	72.5%	—	—
Lorlatinib	71.3%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.4ms